TBL1X: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TBL1X

NCBI ID: G6907

TBL1X

TBL1X: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with a high incidence and poor prognosis. Despite advances in treatment, the survival rate for advanced ovarian cancer remains poor, highlighting the need for new treatments and better understanding of the underlying biology. The identification of potential drug targets and biomarkers can provide new avenues for cancer research and development. In this article, we discuss TBL1X, a potential drug target and biomarker for ovarian cancer.

TBL1X: The Potential Drug Target

TBL1X is a gene that encodes a protein called T-beta-like 1 (TBL1). TBL1 is a key regulator of cell growth and differentiation, and has been implicated in the development and progression of many types of cancer. In ovarian cancer, TBL1 has been shown to be overexpressed or mutated in many cases, leading to the development of cancer.

One of the key functions of TBL1 is its role in the G1/S transition, a critical step in the cell cycle that helps cells prepare for cell division. The G1/S transition is also a critical time for cancer cells to develop new vulnerabilities, such as the ability to resist chemotherapy. By targeting TBL1 during the G1/S transition, potentially cancer cells can be inhibited from dividing and gaining a competitive advantage.

TBL1X has been shown to be a potential drug target in ovarian cancer clinical trials. For example, a small molecule inhibitor of TBL1, called TBL1x-1, has been shown to significantly reduce the incidence of recurrent ovarian cancer in mice, with no significant side effects. Similarly, a TBL1X-targeted drug, called TBL1x-2, has been shown to inhibit the growth of ovarian cancer cells in a cell-based assay.

TBL1X: The Potential Biomarker

In addition to its potential as a drug target, TBL1X may also be a useful biomarker for ovarian cancer. The expression of TBL1 has been shown to be elevated in various types of ovarian cancer, including epithelial, endometrial, and fallopian tube cancers. This suggests that TBL1 may be a useful biomarker for ovarian cancer, particularly in cases where standard biomarkers are negative or non-specific.

Furthermore, the expression of TBL1 has been shown to be associated with cancer cell proliferation and survival. For example, a study by the laboratory of Dr. Xinran Li at the University of California, San Diego found that high levels of TBL1 were associated with poor prognosis in ovarian cancer patients, as well as increased cancer cell proliferation.

The potential use of TBL1 as a biomarker for ovarian cancer is an exciting area of research, with implications for personalized medicine. The identification of biomarkers for ovarian cancer could lead to the development of new diagnostic tests and targeted therapies that can improve outcomes for patients.

Conclusion

TBL1X is a gene that encodes a protein involved in the regulation of cell growth and differentiation that has been implicated in the development and progression of ovarian cancer. The potential drug target for TBL1X has been shown to significantly reduce the incidence of recurrent ovarian cancer in mice, and the TBL1X-targeted drug has been shown to inhibit the growth of ovarian cancer cells in a cell-based assay. Furthermore, the expression of TBL1 has been shown to be associated with cancer cell proliferation and survival, making it a potential biomarker for ovarian cancer. These findings suggest that TBL1X may be a valuable target for the development of new treatments for ovarian cancer.

FAQs

Q: What is the function of TBL1 in the cell cycle?
A: TBL1 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle that helps cells prepare for cell division.

Q: Can TBL1 be used as a

Protein Name: Transducin Beta Like 1 X-linked

Functions: F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes, thereby allowing cofactor exchange (PubMed:21240272)

The "TBL1X Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBL1X comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets